A Phase 1/2 Trial of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Thai Infants

reportActive / Technical Report | Accession Number: ADA481707 | Open PDF

Abstract:

The Walter Reed Army Institute of Research WRAIR has produced a tetravalent live-attenuated dengue vaccine that has been well tolerated and immunogenic in U.S. adults and Thai children. As infants are considered by many as an important age group for vaccination in dengue-endemic countries, we evaluated the vaccine in Thai flavivirus-na ve infants who are at risk for dengue.

Security Markings

DOCUMENT & CONTEXTUAL SUMMARY

Distribution:
Approved For Public Release
Distribution Statement:
Approved For Public Release; Distribution Is Unlimited.

RECORD

Collection: TR
Identifying Numbers
Subject Terms